Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in many patients. Using spectrometry-based proteomics, we iden...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:NPJ Precis Oncol
Main Authors: Terp, Mikkel G., Jacobsen, Kirstine, Molina, Miguel Angel, Karachaliou, Niki, Beck, Hans C., Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Cardona, Andrés F., Rosell, Rafael, Ditzel, Henrik J.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282882/
https://ncbi.nlm.nih.gov/pubmed/34267282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00208-w
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker